Gold Nanoparticles in Gene Therapy: From Concept to Clinic‑Ready Platforms

 

Is AuNPs‑based Gene Therapy still “Actual”?

Recent reviews and studies from the last few years continue to frame gold nanoparticles (AuNPs) as promising non‑viral vectors for gene editing and gene silencing, particularly in cancer, infectious disease, and neurological models.

  • A 2022 review on gold nanoparticle–mediated gene therapy highlights AuNPs as versatile carriers for CRISPR/Cas, siRNA, and antisense oligos, emphasizing their tunable surface chemistry and relatively low immunogenicity (Kanu et al., 2022).
  • A 2025 preclinical study in a Parkinson’s rat model reports that AuNPs‑mediated gene therapy can provide long‑term symptomatic relief and reduce neuroinflammation, indicating that serious in vivo work is ongoing, not historical (van der Vyver et al., 2025).
  • Most recently, Cunningham et al. (2026) reported a modular, non‑viral gold‑nanoparticle platform that co‑delivers CRISPR‑Cas9 RNPs and long DNA templates into primary human blood cells. The authors show that these AuNPs formulations can efficiently edit hematopoietic and immune cells while preserving viability, and they emphasize benchtop assembly, scalability, and compatibility with clinically relevant gene‑editing workflows, positioning AuNPs as a realistic candidate for future ex vivo gene‑therapy applications.
  • Market analyses also project continued growth of gold‑nanoparticle use in biomedical applications, including theranostics and drug/gene delivery, over the coming decade (Strategic Market Research, 2025).

So AuNPs remain a current, actively evolving platform, but they coexist with, rather than replace, LNPs and viral vectors.

Current Trends in AuNPs‑mediated Gene Therapy

1. AuNPs for CRISPR‑based Gene Editing

Gold nanoparticles have become a leading non‑viral scaffold for delivering CRISPR components: either as plasmids, mRNA, or pre‑assembled RNP complexes, directly into hard‑to‑transfect cells.

  • CRISPR‑Gold: A landmark platform known as “CRISPR‑Gold” uses AuNPs to co‑deliver Cas9 RNP and donor DNA, achieving homology‑directed repair (HDR) in vivo with reduced off‑target toxicity compared with electroporation or viral vectors. This formulation was shown to correct disease‑relevant mutations and suppress pathological phenotypes in preclinical models, highlighting the potential of AuNPs for in vivo gene correction (Lee et al., 2017).
  • Editing hematopoietic stem cells: Researchers at Fred Hutchinson Cancer Center demonstrated that AuNPs loaded with CRISPR tools can edit a rare subset of human blood stem cells, a key target for durable therapies against HIV and inherited hemoglobinopathies. The optimized ~19 nm AuNPs efficiently trafficked to the nucleus and achieved gene editing in 10–20% of cells without toxic electric pulses, with edited cells persisting in bone marrow and lymphoid organs in vivo (Shahbazi et al., 2019). Cunningham et al. (2026) showed that a gold‑nanoparticle CRISPR system can non‑virally deliver gene editors and long DNA templates into primary blood cells at two different genomic sites, in two cell types, without using electroporation or engineered Cas9 variants. Although its editing efficiency is lower than that achieved with viral vectors or electroporation, the underlying CRISPR‑AuNP platform appears scalable, substantially cheaper than viral approaches, and well suited for future in vivo testing in humanized mouse models, particularly for stem and immune cell engineering.

These studies suggest that AuNPs‑CRISPR platforms may enable safer, scalable ex vivo and in vivo gene editing for blood disorders, immune diseases, and many monogenic conditions.

2. Cancer Gene Silencing and Theranostics

There is a strong focus on combining gene delivery with imaging and photothermal therapy resulting in multi‑modal “theranostic” strategies.

  • Targeted siRNA delivery: AuNPs functionalized with tumor‑targeting ligands and loaded with siRNA have been used to silence genes involved in proliferation, angiogenesis, and metastatic signaling, leading to potent tumor growth inhibition in preclinical cancer models (Mendes et al., 2017, Darmadi et al., 2024). Beyond solid tumors, Deng et al. (2018) demonstrated that nuclear‑localization‑signal-functionalized gold nanoparticles co‑carrying an anti‑miR‑221 oligonucleotide and the AS1411 aptamer can reprogram an epigenetic signaling axis (NCL/miR‑221/NFκB/DNMT1) in aggressive acute myeloid leukemia, reducing DNMT1 levels, restoring tumor‑suppressor gene expression, and markedly inhibiting leukemic proliferation and disease burden in a preclinical AML model.
  • Combination with photothermal therapy: Reviews and application papers describe AuNPs as theranostic platforms for cancer, co‑delivering siRNA and drugs, enabling imaging, and providing plasmonic photothermal therapy in a single construct (Yeh et al., 2012, Zhu et al., 2017, Darmadi et al., 2024).

Such multi‑functional AuNP platforms align well with precision oncology initiatives, where genetic modulation, imaging, and localized therapy can be integrated into a single nanoscale assemble (Kong et al., 2017).

3. Polymer‑ and Ligand‑Engineered AuNPs Vectors

Surface engineering is a major trend:

  • AuNPs functionalized with PEG and cationic polymers such as PEI have been shown to deliver plasmid DNA and siRNA with transfection efficiencies comparable to, and in some cases exceeding, those of commercial lipoplex systems like Lipofectamine 2000 in specific cell lines, while often reducing toxicity. (Ortega-Muñoz et al., 2016, Encabo-Berzosa, et al., 2017, Huang et al., 2024).
  • Recent reviews emphasize ligand‑decorated AuNPs (antibodies, peptides, aptamers) as “precision” gene vectors targeting specific cancer or immune cell populations (Kumar et al., 2019, Craciun et al., 2023, Eker et al., 2024).

4. Safety, Biodistribution, and Regulatory Focus

More work now targets long‑term safety and clinical translation:

  • Recent broad reviews of AuNPs in biomedical and clinical applications discuss size‑dependent biocompatibility, biodistribution, and excretion in detail, and summarize early‑stage clinical trials using AuNPs for therapy and imaging (Anik et al., 2022, Huang et al., 2023).
  • There is active discussion about chronic accumulation, organ deposition, and how surface coatings can mitigate toxicity, reflecting a maturing field moving toward realistic translational endpoints (Yao et al., 2023).

Why AuNPs have not Advanced as Fast as LNPs or Viral Vectors

Several forces may explain the slower clinical trajectory. First, viral vectors already dominate approved gene therapy because they deliver very high transduction efficiency and long-term expression in many settings. Second, LNPs reached the clinic rapidly for RNA delivery and now benefit from real-world manufacturing, formulation, and regulatory experience that AuNPs do not yet match (Shan et al., 2022, Geng et al., 2025).

AuNPs also face a translational challenge that is specific to inorganic nanomaterials: long-term biodistribution, tissue retention, and clearance remain more difficult to characterize than for some biodegradable carriers. Reviews of clinical and translational AuNP research repeatedly identify chronic accumulation, organ deposition, and long-term toxicology as issues that still need deeper resolution before broad gene therapy adoption is likely (Anik et al., 2022, Yao et al., 2023).

How Current Trends Compare with Gold Nanoparticles

1. Lipid Nanoparticles

LNPs currently lead among non-viral gene-delivery systems for RNA medicines because they already have strong clinical precedent and well-developed manufacturing pathways. Compared with AuNPs, LNPs are better positioned for systemic nucleic acid delivery today, but they are often less useful for built-in imaging, photothermal effects, and highly rigid, structurally defined conjugation architectures (Shan et al., 2022, Anik et al., 2022, Pozzi et al., 2023).

2. Viral Vectors

Viral vectors remain the benchmark for durable in vivo gene expression, but they come with known limitations in payload, immunogenicity, and manufacturing complexity. AuNPs compare favorably when the goal is transient, non-integrating delivery, especially for editing or silencing workflows where repeated dosing or multifunctionality may matter more than long-term expression (Kanu et al., 2022, Anik et al., 2022).

3. Polymeric and Hybrid Nanoparticles

Polymeric systems remain important because they can be biodegradable and chemically tunable, but they often show greater formulation variability and can introduce cationic toxicity challenges. Hybrid platforms that combine AuNP cores with polymer or lipid shells are increasingly attractive because they may preserve the imaging and surface-control advantages of gold while improving biocompatibility and release behavior (Suk et al., 2016, Shan et al., 2022, Kanu et al., 2022).

Illustrative overview of Delivery Platforms

 Feature Viral vectors (AAV/lenti) Lipid nanoparticles (LNPs) Polymer NPs (e.g. PEI, PLGA) Gold nanoparticles (AuNPs)
Gene delivery efficiency Very high in target tissues High, especially to liver Moderate–high, formulation‑dependent High with optimized size/surface
Payload size flexibility Limited (e.g., AAV < 4.7 kb) Flexible for RNA, some DNA Flexible; depends on design Flexible for DNA/RNA/RNP conjugation
Duration of expression Long‑term/integrative or episomal Transient Mostly transient Transient/modulatable
Immunogenicity Significant; preexisting immunity Moderate innate responses Variable; can be reduced by design Generally low, surface‑dependent
Manufacturing complexity High; biologics‑like High but maturing fast Moderate–high Relatively straightforward, scalable
Multifunctional theranostics Limited Limited optical features Possible with extra labels Intrinsic imaging/photothermal utility

 

Future Developments to Watch

The most plausible path forward is not immediate head-to-head replacement of LNPs or viral vectors, but selective entry into niches where AuNPs offer unique value. Those niches likely include localized cancer gene therapy, theranostic platforms, photothermal-gene therapy combinations, and ex vivo editing workflows where clearance concerns are less limiting.

Three developments may be especially worth watching:

  • First‑in‑human AuNPs gene vector trials: Groups working on CRISPR‑Gold, blood‑stem‑cell editing, and CNS gene delivery are explicitly positioning their systems for translation; expect early‑phase trials if safety, efficiency, and partnering fall into place (Lee et al., 2017, Shahbazi et al., 2019, Duan et al., 2021).
  • Hybrid vectors: Combining AuNP cores with lipid or polymer shells could leverage AuNPs imaging/photothermal advantages plus LNP/polymer delivery performance, a direction highlighted in recent non‑viral vector reviews (Jiao et al., 2024).
  • Indication niches: AuNP gene vectors may first appear in high‑value niches where their optical or targeting features are critical: e.g., localized tumor gene therapy with photothermal activation, or ex vivo editing of blood cells where clearance is less of an issue (Craciun et al., 2023, Darmadi et al., 2024) .

What does it Mean for the Field

  • Still relevant: AuNP‑based gene therapy is not a passing trend; it remains a current, actively researched non‑viral platform, especially attractive where imaging, photothermal effects, and precise surface engineering matter.
  • Positioning: In today’s landscape, LNPs dominate mainstream clinical RNA delivery, viral vectors dominate long‑term in vivo expression, and AuNPs occupy a high‑value niche in precision, theranostic, and combination gene therapy strategies.
  • Future direction: One may expect more hybrid platforms (AuNP–polymer, AuNP–lipid), more CRISPR RNP delivery work, and deeper safety/biodistribution studies as the field pushes AuNP vectors toward clinical reality.

To explore our gold nanoparticle products designed for gene delivery, imaging, and nano‑enabled therapeutics, please visit Gold Nanoparticles Products.

References:

1. Anik, M. I., Mahmud, N., Al Masud, A., & Hasan, M. M. (2022). Gold nanoparticles (GNPs) in biomedical and clinical applications: A review. Nano Select, 3, 792–821. https://doi.org/10.1002/nano.202100255

2. Craciun, B. F., Clima, L., Bostiog, D.-I., Silion, M., Calin, M., Peptanariu, D., & Pinteala, M. (2023). Multilayer gold nanoparticles as non-viral vectors for targeting MCF-7 cancer cells. Biomaterials Advances, 144, 213201. https://doi.org/10.1016/j.bioadv.2022.213201

3. Cunningham, R. A., Gottimukkala, K. S. V., Lane, D. D., Poljakov, K., Lipson, P., Enstrom, M. R., Rizzi, A., Chapuis, A. G., & Adair, J. E. (2026). Nonviral Gold Nanoparticle-Mediated Delivery of CRISPR-Cas9 Ribonucleoprotein and Long DNA Transgenes Into Primary Blood Cells. Advanced NanoBiomed Research, 0, e202500242. https://doi.org/10.1002/anbr.202500242

4. Darmadi, J., Anwar, A., & Anuar, N. A. S. (2024). Current Progress on Gold Nanoparticle-Mediated Gene Delivery for Human Cancer Treatment. E3S Web of Conferences, 488, Article 03020. https://doi.org/10.1051/e3sconf/202448803020

5. Duan, L., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., & Liang, Y. (2021). Nanoparticle delivery of CRISPR/Cas9 for genome editing. Frontiers in Genetics, 12, 673286. https://doi.org/10.3389/fgene.2021.673286

6. Eker, F., Akdaşçi, E., Duman, H., Bechelany, M., & Karav, S. (2024). Gold Nanoparticles in Nanomedicine: Unique Properties and Therapeutic Potential. Nanomaterials (Basel, Switzerland), 14(22), 1854. https://doi.org/10.3390/nano14221854

7. Encabo-Berzosa, M. M., Sancho-Albero, M., Sebastian, V., Irusta, S., Arruebo, M., Santamaria, J., & Martín Duque, P. (2017). Polymer functionalized gold nanoparticles as nonviral gene delivery reagents. The journal of gene medicine, 19(6-7), 10.1002/jgm.2964. https://doi.org/10.1002/jgm.2964

8. Geng G., Xu Y., Hu Z. et al. (2025). Viral and non-viral vectors in gene therapy: current state and clinical perspectives. eBioMedicine, 2025; 118. https://doi.org/10.1016/j.ebiom.2025.105834

9. Huang, H., Liu, R., Yang, J., Dai, J., Fan, S., Pi, J., Wei, Y., & Guo, X. (2023). Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy. Pharmaceutics, 15(7), 1868. https://doi.org/10.3390/pharmaceutics15071868

10. Huang, P. T., Chen, Y. L., Lin, Y. H., Wang, C. C., & Chang, H. T. (2024). Functional gold nanoparticles for analysis and delivery of nucleic acids. Journal of food and drug analysis, 32(3), 252–273. https://doi.org/10.38212/2224-6614.3514

11. Jiao L., Sun Z., Sun Z., Liu J., Deng G. and Wang X. (2024) Nanotechnology-based non-viral vectors for gene delivery in cardiovascular diseases. Front. Bioeng. Biotechnol. 12:1349077. https://doi.org/10.3389/fbioe.2024.1349077

12. Kanu, G. A., Parambath, J. B. M., Abu Odeh, R. O., & Mohamed, A. A. (2022). Gold nanoparticle-mediated gene therapy. Cancers, 14(21), 5366. https://doi.org/10.3390/cancers14215366

13. Kong, F. Y., Zhang, J. W., Li, R. F., Wang, Z. X., Wang, W. J., & Wang, W. (2017). Unique Roles of Gold Nanoparticles in Drug Delivery, Targeting and Imaging Applications. Molecules (Basel, Switzerland), 22(9), 1445. https://doi.org/10.3390/molecules22091445

14. Kumar, S., Diwan, A., Singh, P., Gulati, S., Choudhary, D., Mongia, A., Shukla, S., & Gupta, A. (2019). Functionalized gold nanostructures: promising gene delivery vehicles in cancer treatment. RSC advances, 9(41), 23894–23907. https://doi.org/10.1039/c9ra03608c

15. Lee, K., Conboy, M., Park, H. M., Jiang, F., Kim, H. J., Dewitt, M. A., Mackley, V. A., Chang, K., Rao, A., Skinner, C., Shobha, T., Mehdipour, M., Liu, H., Huang, W. C., Lanphier, E., Sharma, S., Doudna, J. A., Conboy, I., & Murthy, N. (2017). Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nature Biomedical Engineering, 1, 889–901. https://doi.org/10.1038/s41551-017-0137-2

16. Mendes, R., Fernandes, A. R., & Baptista, P. V. (2017). Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer-The Case for Combined Delivery?. Genes, 8(3), 94. https://doi.org/10.3390/genes8030094

17. Ortega-Muñoz, M., Giron-Gonzalez, M. D., Salto-Gonzalez, R., Jodar-Reyes, A. B., De Jesus, S. E., Lopez-Jaramillo, F. J., Hernandez-Mateo, F., & Santoyo-Gonzalez, F. (2016). Polyethyleneimine-coated gold nanoparticles: Straightforward preparation of efficient DNA delivery nanocarriers. Chemistry – An Asian Journal, 11(24), 3365–3373. https://doi.org/10.1002/asia.201600951

18. Pozzi, D., & Caracciolo, G. (2023). Looking back, moving forward: Lipid nanoparticles as a promising frontier in gene delivery. ACS Pharmacology & Translational Science, 6(11), 1561–1573. https://doi.org/10.1021/acsptsci.3c00185

19. Shahbazi, R., Sghia-Hughes, G., Reid, J. L., Kubek, S., Haworth, K. G., Humbert, O., Kiem, H.-P., & Adair, J. E. (2019). Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations. Nature Materials, 18, 1124–1132. https://doi.org/10.1038/s41563-019-0385-5

20. Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022). Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharmaceutica Sinica B, 12(7), 3028–3048. https://doi.org/10.1016/j.apsb.2022.02.025

21. Sibuyi, N. R. S., Moabelo, K. L., Fadaka, A. O., Meyer, S., Onani, M. O., Madiehe, A. M., & Meyer, M. (2021). Multifunctional Gold Nanoparticles for Improved Diagnostic and Therapeutic Applications: A Review. Nanoscale research letters, 16(1), 174. https://doi.org/10.1186/s11671-021-03632-w

22. Strategic Market Research. (2025). Gold nanoparticles market by product type (spherical, rod-shaped, gold nanocages); by application (drug delivery, diagnostics, therapeutics, environmental & energy); by end user (healthcare, electronics, environmental, industrial); by geography, segment revenue estimation, forecast, 2024–2030 (Report ID 29429571). https://www.strategicmarketresearch.com/market-report/gold-nanoparticles-market

23. Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016). PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced Drug Delivery Reviews, 99, 28–51. https://doi.org/10.1016/j.addr.2015.09.012

24. van der Vyver, S., Mabandla, M. V., & Msibi, Z. N. P. (2025). The long-term effects of gold nanoparticles as gene vectors in a 6-hydroxydopamine-induced parkinsonian rat model. Brain Disorders, 17, 100195. https://doi.org/10.1016/j.dscb.2025.100195

25. Yao, L., Bojic, D., & Liu, M. (2023). Applications and safety of gold nanoparticles as therapeutic devices in clinical trials. Journal of pharmaceutical analysis, 13(9), 960–967. https://doi.org/10.1016/j.jpha.2023.06.001

26. Yeh, Y. C., Creran, B., & Rotello, V. M. (2012). Gold nanoparticles: preparation, properties, and applications in bionanotechnology. Nanoscale, 4(6), 1871–1880. https://doi.org/10.1039/c1nr11188d

27. Zhu, H., Liu, W., Cheng, Z., Yao, K., Yang, Y., Xu, B., & Su, G. (2017). Targeted Delivery of siRNA with pH-Responsive Hybrid Gold Nanostars for Cancer Treatment. International Journal of Molecular Sciences, 18(10), 2029. https://doi.org/10.3390/ijms18102029

      Back to Gold ApplicationsDiscover our Gold Nanoparticles Products